HUTCHMED Completes GSK License Deal for KRAS-EGFR Conjugate Outside China
HUTCHMED said its license agreement with a GSK subsidiary for HMPL-A830 has closed, covering markets outside China, Hong Kong, Macau and Taiwan. An upfront payment of $110 million is expected.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
HUTCHMED (China) Limited said that, after customary closing conditions including antitrust reviews, the exclusive development and license agreement between HUTCHMED Limited and a subsidiary of GSK plc has been completed. Under the deal, the GSK unit gets worldwide rights to develop and sell HMPL-A830, excluding Mainland China, Hong Kong, Macau and Taiwan.
HMPL-A830 is an antibody-targeted therapy conjugate that pairs a KRAS small-molecule inhibitor with an anti-EGFR antibody, aimed at tumors such as colorectal, pancreatic and lung cancers. A global Phase Ia trial began in September 2026. HUTCHMED handles the global Phase I program, while GSK takes over later development and commercialization in its territory.
HUTCHMED expects an upfront payment of $110 million shortly, plus potential milestones of up to $1.185 billion and tiered royalties on annual net sales.
why it matters
For markets this is mainly a company-level event. The upfront payment and possible milestones matter for HUTCHMED's finances, while GSK's involvement signals continued big-pharma interest in oncology pipelines.
market impact
Pharma sector: affects HUTCHMED and GSK shares; limited relevance for the broader market.
tags
instruments
sources
- HUTCHMED Announces Closing of KRAS-EGFR-Antibody Conjugate Therapy License to GSK Outside China — globenewswire.com, 21 October 2026 at 00:00 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗